Novo Nordisk CEO flags 1.5 million US users of compounded GLP-1 drugs

Core Insights - Novo Nordisk's CEO Mike Doustdar highlighted that up to 1.5 million patients in the U.S. may be using compounded versions of GLP-1 drugs, indicating a significant market for cheaper, unapproved alternatives [1] Company Summary - The mention of 1.5 million patients suggests a substantial demand for GLP-1 drugs, which are known for their effectiveness in treating conditions like obesity and diabetes [1] - The existence of compounded versions points to a potential challenge for Novo Nordisk, as these alternatives may impact the sales of their approved products [1] Industry Summary - The trend of patients opting for compounded drugs reflects broader issues in the pharmaceutical industry regarding drug pricing and accessibility [1] - The rise of unapproved alternatives may lead to increased scrutiny and regulatory discussions surrounding the approval processes for such medications [1]